Play an ADAGIO with a STRADIVARIUS: the right patient for CB1 receptor antagonists?
Di Marzo
Vincenzo
V
Italian National Research Council, Pozzuoli, Naples, Italy. vdimarzo@icmib.na.cnr.it
D019440:Anti-Obesity Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002318:Cardiovascular Diseases / Q000209:etiology / Q000378:metabolism / Q000517:prevention & control*; D006801:Humans; D050152:Intra-Abdominal Fat / Q000187:drug effects* / Q000378:metabolism; D009765:Obesity / Q000150:complications / Q000188:drug therapy* / Q000378:metabolism; D018579:Patient Selection; D010880:Piperidines / Q000009:adverse effects / Q000627:therapeutic use*; D011720:Pyrazoles / Q000009:adverse effects / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D043884:Receptor, Cannabinoid, CB1 / Q000037:antagonists & inhibitors* / Q000378:metabolism; D000077285:Rimonabant; D018570:Risk Assessment; D016896:Treatment Outcome
D019440:Anti-Obesity Agents; D010880:Piperidines; D011720:Pyrazoles; D043884:Receptor, Cannabinoid, CB1; D000077285:Rimonabant